Fulcrum Therapeutics, Inc.
NASDAQ:FULC
7.27 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 80 | 2.805 | 6.342 | 19.163 | 8.823 |
| Cost of Revenue
| 1.593 | 0 | 2.414 | 2.515 | 2.379 |
| Gross Profit
| 78.407 | 2.805 | 3.928 | 16.648 | 6.444 |
| Gross Profit Ratio
| 0.98 | 1 | 0.619 | 0.869 | 0.73 |
| Reseach & Development Expenses
| 63.386 | 71.801 | 76.782 | 69.701 | 59.042 |
| General & Administrative Expenses
| 36.448 | 41.668 | 41.694 | 30.516 | 21.392 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 36.448 | 41.668 | 41.694 | 30.516 | 21.392 |
| Other Expenses
| 2.063 | 0 | 2.69 | 0.207 | 0.792 |
| Operating Expenses
| 101.897 | 113.469 | 118.476 | 100.217 | 80.434 |
| Operating Income
| -21.897 | -110.664 | -112.561 | -81.054 | -71.611 |
| Operating Income Ratio
| -0.274 | -39.452 | -17.749 | -4.23 | -8.116 |
| Total Other Income Expenses Net
| 12.172 | 13.329 | 2.69 | 0.207 | 0.792 |
| Income Before Tax
| -9.725 | -97.335 | -109.871 | -80.847 | -70.819 |
| Income Before Tax Ratio
| -0.122 | -34.701 | -17.324 | -4.219 | -8.027 |
| Income Tax Expense
| 0 | 0 | -4.25 | -2.515 | -2.379 |
| Net Income
| -9.725 | -97.335 | -105.621 | -78.332 | -68.44 |
| Net Income Ratio
| -0.122 | -34.701 | -16.654 | -4.088 | -7.757 |
| EPS
| -0.17 | -1.59 | -2.35 | -2.22 | -2.7 |
| EPS Diluted
| -0.17 | -1.59 | -2.35 | -2.22 | -2.7 |
| EBITDA
| -18.241 | -108.492 | -109.72 | -78.539 | -69.232 |
| EBITDA Ratio
| -0.228 | -38.678 | -17.301 | -4.098 | -7.847 |